Aptevo Therapeutics INC 10-Q quarterly reports

Aptevo Therapeutics Inc. reported continued net losses and a substantial accumulated deficit, raising substantial doubt about its ability to continue as a going concern, despite recent financing efforts.

Aptevo Therapeutics reported a net loss of $6.7 million for Q1 2026, with cash and cash equivalents decreasing to $14.5 million, while advancing its clinical pipeline.

Aptevo Therapeutics reported increased net losses for Q3 2025 but significantly strengthened its cash position through recent equity offerings, extending its cash runway into late 2026, while also announcing positive clinical data for mipletamig.

Aptevo Therapeutics reported continued losses and a going concern warning despite recent capital raises and positive clinical data for its lead cancer immunotherapy candidate.

Aptevo Therapeutics reports a net loss of $6.4 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while continuing clinical trials and seeking additional funding.

Aptevo Therapeutics reports a net loss of $17.8 million for the nine months ended September 30, 2024, and discusses ongoing clinical trials and recent financing activities.

Aptevo Therapeutics reported a net loss of $12.7 million for the first half of 2024 and highlighted substantial doubt about its ability to continue as a going concern, despite ongoing clinical development of its immuno-oncology candidates.

Aptevo Therapeutics reported a net loss of $6.8 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.